Krystal Biotech Q2 revenue $70.3M; net income $15.6M; three pipeline readouts on track

Krystal Biotech, Inc.

2024-Q2 EPS reported $0.56 revenue$115,535,000

VYJUVEK net product revenue $70.3M in Q2 2024, up 55.3% vs Q1 2024.
Net income $15.6M ($0.53 diluted EPS) vs net loss ($33.2M) in Q2 2023.
Cash and investments $628.9M at June 30, 2024; strong balance sheet.
On track for three clinical data readouts in 2H 2024: KB301 (3Q), KB408 (4Q), KB707 (4Q).
Received Rare Pediatric Disease Designation for intratumoral KB707 for osteosarcoma in May 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.